A Multi-Center, Open-Label, Single 60 mg Dose, Two Period, Two Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Two Solid Oral Pimasertib Formulations in Cancer Patients

Trial Profile

A Multi-Center, Open-Label, Single 60 mg Dose, Two Period, Two Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Two Solid Oral Pimasertib Formulations in Cancer Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Pimasertib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors EMD Serono
  • Most Recent Events

    • 24 Aug 2014 Status changed from active, no longer recruiting to completed as reported by M.D. Anderson Cancer Center record.
    • 04 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 02 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top